Dealbreaker on MSN2h
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal
By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...
Anemia Treatment Market Poised For Strong Growth, Expected To Hit USD 19.1 Billion By 2033
Global Anemia Treatment Market size is expected to be worth around USD 19.1 Billion by 2033, from USD 9.7 Billion in 2023, growing at a CAGR of 7.2% Lawrence John Prudour +91 91308 55334 ...
Yicai Global16h
US' FibroGen to Sell China Unit to AstraZeneca for USD160 Million
AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...
FibroGen to sell China business, extend cash runway to focus on cancer drugs
The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...